This study compares harvest and hematological recovery data of 100 lymphoma patients who underwent BM harvest either after a short course of G-CSF (16 g/kg for 3 days) (n = 57) or in steady-state conditions (n = 43). G-CSF allowed the attainment of a significantly higher median number of total nucleated cells × /l and to platelets Ͼ20 × 10 9 /l was 12, range 10-14, and 13, range 10-18, days, respectively) than in those autotransplanted with steady-state BM (median time to PMN Ͼ0.5 × 10 9 /l and to platelets Ͼ20 × 10 9 /l 13, range 10-18 and 14, range 10-20 days, respectively, P = 0.004 and P = 0.01). Transfusional requirement was significantly different and patients of the G-CSF group needed shorter hospitalization (17 days, range 12-24, vs 20 days, range 14-32; P = 0.02). These data suggest that treating patients with G-CSF before BM harvest improves the quality of the harvest and accelerates engraftment and hematological recovery.
recently, fewer randomized trials 8, 9 showed that granulocyte colony-stimulating factor (G-CSF)-primed PBSC shorten the time to platelet and neutrophil recovery, as well as the time spent in hospital, as compared with steady-state BM transplantation. In moving from steady-state BM to stimulated PB as the source of hematopoietic progenitors, an intermediate step must be considered: G-CSF-stimulated BM. Recently, in a randomized trial of autologous G-CSFprimed BM vs G-CSF-primed PBSC transplantation in lymphoma patients, we confirmed some previous uncontrolled observations, [10] [11] [12] in particular that engraftment with primed BM is only slightly and not significantly slower than with PBSC. 13 In the present study we focus on the results obtained in a group of patients with non-Hodgkin's lymphoma (NHL) who underwent BM harvesting after a brief course of G-CSF; data are then compared with those obtained in an historical control group of patients with NHL with the same clinical characteristics, autotransplanted with steady-state BM.
Patients and methods
Between February 1995 and March 1998, at the Bone Marrow Transplantation Department of the Udine University Hospital, 57 consecutive patients with high-or intermediate-risk NHL in first or further complete remission (CR) or in partial remission (PR) and eligible for autologous transplantation underwent BM harvesting after a brief course of G-CSF.
Previously, between January 1994 and February 1995, 43 consecutive patients with no differences in diagnosis and clinical features had undergone steady-state BM harvest. This last group of patients was used as an historical control, and harvest-and transplant-related data between the two groups were compared. Our program for NHL includes six cycles of F-MACHOP therapy 14 followed by harvest (with or without G-CSF priming) within 3 months of the end of therapy and, when needed, by radiotherapy to residual masses. Within 8-10 months from harvest, the majority of patients were transplanted. While harvest procedures were performed without G-CSF prior to February 1995 and with G-CSF after that date, the transplant procedures have in part overlapped, since some of the historical patients were transplanted after February 1995. It must be emphasized that, apart from the use of G-CSF, there were no other differences in the management of patients between the two groups. Patient characteristics are summarized in Table 1 . 18 22 In the more recent group of treated patients, recombinant human G-CSF (Filgrastim; Granulokine Roche, Milan or Neupogen; Dompè Biotec, Milan, Italy) was administered at a daily dose of 16 g/kg given as a single s.c. afternoon injection for 3 days. BM was harvested on day 4, 15-18 h after the third dose of G-CSF, under general anesthesia. In both groups, total nucleated cells (TNC) and mononuclear cells (MNC) were determined with an automated cell counter (Cell Dyn 300 Abbott, Santa Clara, CA, USA) during harvesting, and the harvest was stopped when at least 0.4 × 10 8 /kg bw MNC had been collected. BM cells harvested were processed on a Fenwall CS3000 separator (Baxter Health Care Products, Deerfield, IL, USA) and cryopreserved in 10% dimethylsulfoxide using a controlled rate liquid nitrogen freezer and the vapor phase of liquid nitrogen. Enumeration of CD34
+ cells was performed incubating 1 × 10 6 cells with the phycoerythrin-conjugated (PE) moAb HPCA-2 (CD34) and the FITC moAb HLE-1 (CD45); erytrocytes were then lysed with the FACS Lysing solution (Becton Dickinson, Milan, Italy). Samples were washed twice with phospate-buffered saline and then analyzed using a FACScan flow cytometer (Becton Dickinson). Forty-five thousand CD45-positive events or at least 100 CD34-positive events were acquired according to the ISH-AGE protocol, using a cumulative gating strategy to identify true CD34-positive cells and minimize the number of nonspecifically stained events. 15 Negative controls for each sample were also analyzed (using FITC and PE irrelevant isotypic immunoglobulins). Data on CD34-positive cells were not available for the historical control group. Day 14 CFU-GM were detected by plating in duplicate 10 5 light density cells in a total volume of 1 ml of IMDM medium (Iscove's modified Dulbecco's medium, Gibco, Grand Island, NY, USA) brought to 25% with fetal calf serum (Stem Cell Corp, Vancouver, Canada) and supplemented with 0.8% methylcellulose and G-CSF, GM-CSF and interleukin-3 (all at the final concentration of 50 ng/ml) in 35-mm tissue culture dishes.
High-dose therapy and patient care
The conditioning regimen used for NHL was a modified The cryopreserved BM was thawed and reinfused on day 0, at least 24 h after completion of chemotherapy (CHT). After transplant, all patients received subcutaneous filgrastim at a daily dose of 5 g/kg bw starting on day +4 and up to a neutrophil count in excess of 1 × 10 9 /l for 3 consecutive days.
Patients were treated in private rooms with reverse isolation and a diet low in bacterial and fungal content. They received antimicrobial, antimycotic and antiviral prophylaxis with trimethoprim-sulphametoxazole or ciprofloxacin, itraconazole, nystatin or amphotericin suspensions and acyclovir, respectively. Parenteral antibiotics were started after the onset of fever у38°C during neutropenia and maintained until the patient had been afebrile for at least 3 consecutive days. First line i.v. antibiotic therapy included teicoplanin and ceftazidime. Platelet transfusions (single donor thromboaphereses) were given if the platelet count fell below 15 × 10 9 /l; packed red blood cells were transfused to maintain a hemoglobin (Hb) level у80 g/l. Complete blood counts and vital signs were monitored daily during the hospital stay. Further post-transplant analyses were performed as necessary. Blood chemistry for liver and renal function were assayed regularly.
Statistical analysis
Quantitative variables were compared by the two-sided ttest for independent samples; time-dependent variables were compared by the log-rank test.
Results
Filgrastim administration was, in general, well tolerated; mild side-effects, such as bone pain, were well controlled 759 Table 2 Harvest-related data: comparison between steady-state and G-CSF pre-treated BM 0001. Moreover, a significantly lower volume of bone marrow was harvested in the group stimulated with G-CSF, with a median volume harvested/patient of 1300 ml (range 825-1892) vs a median of 1445 ml (range 1100-1750), P Ͻ 0.0001, and a median volume harvested/kg bw of 21 ml (8-30) vs 17 ml (range 15-31) P Ͻ 0.0001 in the G-CSF pre-treated and in the historical group, respectively. Only data on TNC and MNC could be compared between the two groups, since data on CD34 + cells were not available for the historical control group. Comparison of harvest related data between the two groups is summarized in Table 2 .
Twenty-six patients in the steady-state BM group and 23 in the G-CSF pre-treated group have been autotrasplanted to date. Viability of reinfused cells evaluated with the Trypan blue test was у90% in all cases. Table 3 shows the comparison of transplant-related data between the two groups of patients. Median number of days to 0.5 × 10 9 /l PMN was 12 (range 10-14) and 13 (range 10-18), P = 0.004, while median number of days to unsupported platelets (у20 × 10 9 /l) was 13 (range 10-18) and 14 (range 10-20), P = 0.015, in the two groups respectively (Figure 1) . A statistically significant difference between the two groups was also observed in the number of blood units and platelet aphereses transfused and in the number of posttransplant G-CSF administrations. A significant difference in days of hospitalization was also observed: patients autotransplanted with pre-treated BM were discharged from hospital 3 days earlier: 17 (range 12-24) vs 20 days (range 14-32), P = 0.02.
Discussion
The effects of G-CSF on BM have been largely studied both in vitro and in vivo. They include an increase in marrow cellularity and in the myeloid:erythroid ratio as well as an amplification of the myeloid compartment. Despite many laboratory and experimental observations, there are few and controversial data concerning the clinical use of pre-treated BM as a source of hematopoietic progenitor cells and its possible role in transplantation. The early studies by Johnsen et al 16 in 1992 and Hansen et al 17 in 1995 showed no significant advantages in terms of engraftment and hematological recovery in autologous transplantation with BM cells stimulated with G-CSF. More recently other studies [10] [11] [12] showed that the engraftment potential of pro- genitor cells harvested from pre-stimulated BM is similar to that of primed PB, both being superior to steady-state BM. In the only randomized trial published to date, we have compared the outcome of autologous transplantation performed with G-CSF-pre-treated BM to that performed with PB stem cells and showed few differences in the engraftment kinetics between the two groups. 13 In the present study we report our experience in 57 consecutive and homogeneously treated patients with nonHodgkin's lymphoma, in whom BM was harvested for autologous transplantation after a brief course of G-CSF. Patients were harvested after chemotherapy (with only seven patients undergoing more than one line of treatment), all having obtained a complete or at least partial response (the refractory and relapsed cases were excluded). According to our previous experience, 13 we administered 16 g/kg bw of G-CSF for 3 days before the harvest. The number of MNC harvested was compared with the number obtained in an historical control group of 43 lymphoma patients with the same clinical characteristics, in which BM was collected in steady-state conditions: pre-stimulation yielded a higher number of MNC/kg and MNC/kg/l, with a significantly lower volume of marrow collected.
A similar comparison of CD34 + cell content was not possible, because evaluation of CD34 + cells in the historical steady-state BM harvest group was not performed. Nevertheless, CFU-GM/ml of BM were significantly higher in pre-stimulated patients (P = 0.008). The faster speed of hematological recovery in patients autotransplanted with stimulated BM allows speculation that, paralleling what happened for CFU-GM, a higher number of CD34 + cells was collected after G-CSF administration.
Very few data are available on the minimum number of CD34 + BM cells needed for safe and sustained engraftment in the autologous setting. 18 In our series a median number of 0.58 × 10 6 /kg (range 0.02-2.3) BM CD34
+ were harvested after G-CSF stimulation. Even if significantly lower than the number of CD34 + cells usually collected from PB after mobilization with G-CSF, this number not only allowed stable engraftment (as previously reported), but also showed the kinetics of hematological recovery not to be significantly slower than those seen with PB. 13 The biological mechanisms explaining the increase of BM CD34
+ with G-CSF stimulation have still to be clarified. Studies on the biological effects of G-CSF on BM suggest that this cytokine alone may be responsible for a quantitative expansion of the whole CD34
+ population, but that the recruitment or priming of hematopoietic stem cells can occur only through the combined use of two or more cytokines. 19 More recently, Steen et al 20 attempted to explain the mechanisms involved in the mobilization of progenitor cells from BM to PB studying BM and CD34 + cells during steady-state hemopoiesis and during G-CSF administration. They reported that qualitative differences between PB CD34
+ and BM CD34 + cells are present in steady-state conditions and conserved during G-CSF administration. In the BM compartment they observed an increase in the total number of CD34 + cells after G-CSF, as have others. 12, 13 Finally, partial contamination with PB during BM harvesting cannot be excluded, but this cannot explain the engraftment kinetics observed, since the absolute number of CD34 + cells obtained remained well below the number of PB CD34 + cells usually collected. On the basis of these observations, we suggest that the minimum number of CD34 + cells needed for stable engraftment should be recalculated. It must be once more emphasized that all our patients had normal and sustained hematological recovery and no graft failures have so far been observed.
The costs of the pre-treated BM procedure are worth considering. Retrospective cost evaluations of steady-state BM and mobilized PBSC collections and transplantation have led to controversial results, showing in one study an economic advantage for BM 21 and in another for PBSC. 22 Two prospective multicentric randomized trials again compared harvest and transplant cost of steady-state BM with mobilized PBSC and showed that saving with PBSC is mainly due to the shorter hospitalization and reduced supportive post-transplant care. 23, 24 In our experience, no significant differences emerged in costs for harvesting procedures between pre-treated BM and mobilized PB: on one hand, the cost of the operating room and anesthesia must be considered, and on the other, PBSC collection requires more laboratory procedures for monitoring, processing and thawing. As noted in our previous paper, 13 at similar harvesting costs, no post-transplant differences emerged in terms of days of hospitalization, G-CSF doses, transfusion require-761 ments and antibiotic therapy for febrile episodes when pre-treated BM was reinfused. From these observations some other possible roles for stimulated BM transplantation can be hypothesized. In the related donor setting, for instance, this type of collection can be considered a valid alternative to PBSC, with some possible advantages. Considering the different lymphocyte pattern in BM and PB, harvesting pre-treated BM may allow the collection of a safe number of stem cells with a lower number of lymphocytes. A reduced number of reinfused T cells can avoid the need for manipulation of the graft, such as T cell depletion, and can possibly result in a decreased risk of GVHD, and in particular of chronic complications. 25 A small quantity of pre-stimulated BM could provide sufficient CD34 + cells in pediatric allografts. Children, as well as adults with low body weight, are prone to more frequent and severe apheresis side-effects, such as hypocalcemia. Moreover, in small children adequate peripheral venous access for apheresis can also impose a limit to the application of this procedure.
More studies are needed to investigate the biological aspects of pre-treated BM: stem cell number, phenotype and growth characteristics after G-CSF administration, composition of the graft, in particular as far as the CD34 + cells and lymphocyte content are concerned, grade of contamination with PB are all aspects that deserve further investigation.
